Eagle Pharmaceuticals Inc (EGRX)
Company Info
US2697961082
269796108
Feb 12, 2014
Highlights
$15.16M
$0.85
1.38
0.91
$0.00 - $6.81
$17.00
4.19%
3.91
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Eagle Pharmaceuticals Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Eagle Pharmaceuticals Inc had a return of 134.00% year-to-date (YTD) and -80.47% in the last 12 months. Over the past 10 years, Eagle Pharmaceuticals Inc had an annualized return of -28.60%, while the S&P 500 had an annualized return of 11.31%, indicating that Eagle Pharmaceuticals Inc did not perform as well as the benchmark.
EGRX
134.00%
80.00%
-72.85%
-80.47%
-53.38%
-28.60%
^GSPC (Benchmark)
4.46%
2.46%
9.31%
23.49%
13.03%
11.31%
Monthly Returns
The table below presents the monthly returns of EGRX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 60.00% | 134.00% | |||||||||||
| 2024 | 12.05% | 0.00% | -10.58% | -21.95% | -15.16% | 61.38% | -13.93% | 6.64% | -27.43% | -83.91% | 18.33% | -29.58% | -90.44% |
| 2023 | 16.11% | -17.50% | 1.32% | -1.02% | -26.10% | -6.31% | 6.79% | -18.35% | -6.96% | -12.94% | -57.39% | -10.60% | -82.11% |
| 2022 | -9.78% | 3.16% | 4.43% | -10.83% | 5.82% | -4.86% | -10.65% | -17.46% | -19.38% | 19.11% | 15.41% | -19.52% | -42.60% |
| 2021 | 0.21% | -4.65% | -6.20% | -2.18% | -2.96% | 8.03% | 8.64% | 14.77% | 4.52% | -6.11% | -8.96% | 6.80% | 9.34% |
| 2020 | -10.42% | -14.72% | 0.22% | 10.83% | 0.55% | -6.40% | -3.31% | -14.46% | 7.06% | 9.51% | -2.19% | 2.35% | -22.49% |
| 2019 | 4.89% | 18.48% | 0.84% | 1.82% | -1.17% | 9.58% | -1.47% | 2.79% | 0.32% | 10.84% | -6.73% | 2.74% | 49.12% |
| 2018 | 11.89% | -6.07% | -6.15% | -1.29% | 29.61% | 12.24% | 4.74% | -12.77% | 0.29% | -28.98% | 2.36% | -20.06% | -24.58% |
| 2017 | -12.77% | 10.81% | 8.15% | 9.22% | -19.47% | 8.14% | -37.70% | 11.01% | 9.31% | -9.88% | 9.88% | -9.55% | -32.67% |
| 2016 | -18.91% | -11.84% | -36.11% | -6.52% | 25.54% | -18.39% | 11.21% | 38.50% | 17.15% | -20.17% | 41.30% | 0.48% | -10.52% |
| 2015 | 25.23% | 75.17% | 23.21% | 25.81% | 37.82% | 11.33% | 19.49% | -18.70% | -5.75% | -13.94% | 43.84% | -3.24% | 472.06% |
| 2014 | 7.25% | -7.34% | -22.67% | 20.18% | 20.93% | -20.69% | 10.87% | 0.40% | 0.16% | -0.47% | 22.92% | 20.81% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of EGRX is 25, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Eagle Pharmaceuticals Inc (EGRX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Eagle Pharmaceuticals Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Eagle Pharmaceuticals Inc was 99.65%, occurring on Oct 28, 2024. The portfolio has not yet recovered.
The current Eagle Pharmaceuticals Inc drawdown is 98.84%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.65% | Aug 6, 2015 | 2323 | Oct 28, 2024 | — | — | — |
| -37.6% | Mar 10, 2014 | 52 | May 21, 2014 | 155 | Dec 31, 2014 | 207 |
| -16.56% | Jun 23, 2015 | 8 | Jul 2, 2015 | 7 | Jul 14, 2015 | 15 |
| -15.66% | Jan 12, 2015 | 4 | Jan 15, 2015 | 5 | Jan 23, 2015 | 9 |
| -14.8% | Mar 16, 2015 | 8 | Mar 25, 2015 | 5 | Apr 1, 2015 | 13 |
Volatility
Volatility Chart
The current Eagle Pharmaceuticals Inc volatility is 39.99%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Valuation
The Valuation section provides an assessment of the market value of Eagle Pharmaceuticals Inc compared to its peers in the Drug Manufacturers - Specialty & Generic industry.
PE Ratio
The chart displays the price to earnings (P/E) ratio for EGRX in comparison to other companies of the Drug Manufacturers - Specialty & Generic industry. Currently, EGRX has a PE value of 1.4. This PE value is considered to be low compared to the rest of the industry.PEG Ratio
The chart displays the price to earnings to growth (PEG) ratio for EGRX in comparison to other companies of the Drug Manufacturers - Specialty & Generic industry. Currently, EGRX has a PEG value of 0.9. This PEG ratio falls in the average range for the industry.Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Eagle Pharmaceuticals Inc.
Loading data...
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |